MDSpire - Takeaway
From the Journals

Trial Tests Single-Day TRD Treatment 

Randomized trial found more than half of treated patients achieved remission within 8 days.

Share

  • 1

    Inhaled mebufotenin showed efficacy in treatment-resistant depression.

  • 2

    58% of patients achieved remission by day

  • 3

    Mean depression severity decreased by 15.2 points in GH001 group.

  • 4

    23% patients required one dose, 53% two doses.

  • 5

    Psychoactive effects lasted 9-14 minutes.

  • 6

    73% experienced mild to moderate side effects.

  • 7

    Future studies needed for long-term efficacy and safety.

Original Source(s)

Trial Tests Single-Day TRD Treatment 

  • by Andrea Surnit

  • March 26, 2026

Related Content

GLP-1 Drugs Examined in Psychiatric Outcomes

Researchers evaluate mental health trajectories with antidiabetic therapies in patients with depression or anxiety.

Medical Oddities: When Men Face Catcalling

Cooking, catcalling, and colon swaps—medicine keeps things interesting.

Moral Distress Associated With Physician Burnout

Researchers link distress to burnout, professional fulfillment, and intent to leave or reduce clinical hours.